BTTX
Better Therapeutics, Inc. [BTTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BTTX Stock Summary
Top 10 Correlated ETFs
BTTX
Top 10 Correlated Stocks
BTTX
In the News
BTTX Financial details
Company Rating
Neutral
Market Cap
648.74K
Income
-31.57M
Revenue
0
Book val./share
-0.26
Cash/share
0.17
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.28
Forward P/E
-
PEG
0.09
P/S
-
P/B
-0.89
P/C
0.05
P/FCF
-0.42
Quick Ratio
0.51
Current Ratio
0.57
Debt / Equity
-1.44
LT Debt / Equity
-0.78
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
-1.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
7.67%
Inst Trans
1.69%
ROA
-294%
ROE
401%
ROC
13.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.005-1.55
52W High
-
52W Low
-
RSI
29
Rel Volume
0.03
Avg Volume
6.13M
Volume
162.49K
Perf Week
-20.5%
Perf Month
-96.3%
Perf Quarter
-95.66%
Perf Half Y
-96.88%
-
-
-
-
Beta
2.131
-
-
Volatility
0%, 0.06%
Prev Close
-0.62%
Price
0.00795
Change
-11.67%
BTTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | -0.25 | -0.85 | -1.71 | -1.69 | |
| Operating cash flow per share | -0.26 | -0.76 | -1.31 | -1.23 | |
| Free cash flow per share | -0.38 | -1.07 | -1.35 | -1.28 | |
| Cash per share | 0.03 | 0.02 | 1.72 | 0.67 | |
| Book value per share | -0.03 | -0.89 | 1.56 | -0.04 | |
| Tangible book value per share | -0.16 | -1.63 | 1.34 | -0.2 | |
| Share holders equity per share | -0.03 | -0.89 | 1.56 | -0.04 | |
| Interest debt per share | 0.21 | 0.1 | 0.41 | 0.69 | |
| Market cap | 236M | 75.58M | 109.75M | 26.15M | |
| Enterprise value | 240.24M | 76.09M | 78.69M | 25.29M | |
| P/E ratio | -40.72 | -11.83 | -2.72 | -0.66 | |
| Price to sales ratio | 13.11K | 9.45K | 0 | 0 | |
| POCF ratio | -37.96 | -13.09 | -3.56 | -0.9 | |
| PFCF ratio | -26.36 | -9.35 | -3.44 | -0.87 | |
| P/B Ratio | -390.08 | -11.18 | 2.99 | -29.09 | |
| PTB ratio | -390.08 | -11.18 | 2.99 | -29.09 | |
| EV to sales | 13.35K | 9.51K | 0 | 0 | |
| Enterprise value over EBITDA | -42.14 | -12.18 | -2.57 | -0.66 | |
| EV to operating cash flow | -38.64 | -13.18 | -2.55 | -0.87 | |
| EV to free cash flow | -26.83 | -9.42 | -2.47 | -0.84 | |
| Earnings yield | -0.02 | -0.08 | -0.37 | -1.52 | |
| Free cash flow yield | -0.04 | -0.11 | -0.29 | -1.15 | |
| Debt to equity | -8.26 | -0.09 | 0.26 | -16.55 | |
| Debt to assets | 1.02 | 0.1 | 0.19 | 0.65 | |
| Net debt to EBITDA | -0.74 | -0.08 | 1.02 | 0.02 | |
| Current ratio | 2.03 | 0.76 | 9.56 | 1.37 | |
| Interest coverage | -524.82 | -63.23 | -165.19 | -25.66 | |
| Income quality | 1.07 | 0.9 | 0.76 | 0.73 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 122.06 | 306.88 | 0 | 0 | |
| Research and developement to revenue | 127.22 | 372.25 | 0 | 0 | |
| Intangibles to total assets | 0.67 | 0.87 | 0.1 | 0.17 | |
| Capex to operating cash flow | 0.44 | 0.4 | 0.03 | 0.04 | |
| Capex to revenue | -152 | -288.13 | 0 | 0 | |
| Capex to depreciation | -38 | -30.73 | -0.66 | -0.43 | |
| Stock based compensation to revenue | 4.67 | 29.13 | 0 | 0 | |
| Graham number | 0.38 | 4.12 | 7.73 | 1.2 | |
| ROIC | -1.32 | 1.06 | -0.66 | -2.74 | |
| Return on tangible assets | -3.59 | -7.68 | -0.88 | -2.09 | |
| Graham Net | -0.2 | -1.72 | 1.12 | -0.34 | |
| Working capital | 501K | -150K | 40.52M | 4.95M | |
| Tangible asset value | -3.87M | -12.31M | 31.64M | -4.79M | |
| Net current asset value | -4.5M | -12.68M | 31.01M | -5.4M | |
| Invested capital | -8.26 | -0.09 | 0.26 | -16.55 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 424.5K | 1.02M | 2.28M | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 136.16 | 275.09 | 343.36 | 405.93 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.68 | 1.33 | 1.06 | 0.9 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | 9.58 | 0.95 | -1.1 | 44.23 | |
| Capex per share | -0.12 | -0.3 | -0.05 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.48 | -0.37 | -0.39 | -0.24 | -0.15 | |
| Operating cash flow per share | -0.3 | -0.27 | -0.37 | -0.16 | -0.15 | |
| Free cash flow per share | -0.31 | -0.28 | -0.39 | -0.18 | -0.15 | |
| Cash per share | 0.94 | 0.66 | 0.25 | 0.2 | 0.17 | |
| Book value per share | 0.31 | -0.04 | -0.41 | -0.35 | -0.26 | |
| Tangible book value per share | 0.13 | -0.2 | -0.57 | -0.46 | -0.33 | |
| Share holders equity per share | 0.31 | -0.04 | -0.41 | -0.35 | -0.26 | |
| Interest debt per share | 0.64 | 0.65 | 0.63 | 0.47 | 0.36 | |
| Market cap | 41.7M | 26.36M | 16.68M | 33.71M | 14.09M | |
| Enterprise value | 34.18M | 25.5M | 25.15M | 41.73M | 21.8M | |
| P/E ratio | -0.91 | -0.75 | -0.45 | -1.11 | -0.6 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.94 | -4.16 | -1.91 | -6.63 | -2.37 | |
| PFCF ratio | -5.65 | -3.94 | -1.81 | -6.03 | -2.37 | |
| P/B Ratio | 5.75 | -29.32 | -1.7 | -3.12 | -1.42 | |
| PTB ratio | 5.75 | -29.32 | -1.7 | -3.12 | -1.42 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.32 | -3.06 | -2.82 | -6.7 | -4.08 | |
| EV to operating cash flow | -4.87 | -4.02 | -2.89 | -8.2 | -3.67 | |
| EV to free cash flow | -4.63 | -3.81 | -2.72 | -7.46 | -3.66 | |
| Earnings yield | -0.27 | -0.33 | -0.56 | -0.23 | -0.42 | |
| Free cash flow yield | -0.18 | -0.25 | -0.55 | -0.17 | -0.42 | |
| Debt to equity | 2.04 | -16.55 | -1.48 | -1.32 | -1.44 | |
| Debt to assets | 0.52 | 0.65 | 1.14 | 1.22 | 1.33 | |
| Net debt to EBITDA | 0.73 | 0.1 | -0.95 | -1.29 | -1.44 | |
| Current ratio | 2.52 | 1.37 | 0.62 | 0.53 | 0.57 | |
| Interest coverage | -27.08 | -18.96 | -20.71 | -12.48 | 10.31 | |
| Income quality | 0.62 | 0.72 | 0.93 | 0.67 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.15 | 0.17 | 0.29 | 0.31 | 0.26 | |
| Capex to operating cash flow | 0.05 | 0.06 | 0.06 | 0.1 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.52 | -0.5 | -0.69 | -0.63 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.82 | 0.56 | 1.91 | 1.37 | 0.94 | |
| ROIC | -0.5 | -0.6 | -1.9 | -2.05 | -1.22 | |
| Return on tangible assets | -0.47 | -0.46 | -1.03 | -0.95 | -0.74 | |
| Graham Net | 0.06 | -0.34 | -0.7 | -0.52 | -0.37 | |
| Working capital | 14.18M | 4.95M | -5.2M | -6.45M | -5.59M | |
| Tangible asset value | 3.13M | -4.79M | -13.59M | -14.37M | -12.73M | |
| Net current asset value | 2.52M | -5.4M | -14.2M | -14.97M | -13.31M | |
| Invested capital | 2.04 | -16.55 | -1.48 | -1.32 | -1.44 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.17M | 2.15M | 2.77M | 2.75M | 2.65M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 162.75 | 378.85 | 299.56 | 337.08 | 246.99 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.55 | 0.24 | 0.3 | 0.27 | 0.36 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.57 | 9.75 | 0.95 | 0.7 | 0.59 | |
| Capex per share | -0.02 | -0.02 | -0.02 | -0.02 | 0 |
BTTX Frequently Asked Questions
What is Better Therapeutics, Inc. stock symbol ?
Better Therapeutics, Inc. is a US stock , located in San francisco of Ca and trading under the symbol BTTX
What is Better Therapeutics, Inc. stock quote today ?
Better Therapeutics, Inc. stock price is $0.00795 today.
Is Better Therapeutics, Inc. stock public?
Yes, Better Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 6.13M
- Market Capitalization 648.74K
- Employee 54
- CEO Mr. Frank L. Karbe
- Headquarters San Francisco,CA,US
- IPO Date 2021-03-17
-
Website
https://www.bettertx.com 
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
